Methylene Blue Address Vascular-Hypometabolism in Alzheimer's Disease
a year ago
- #Alzheimer's Disease
- #Methylene Blue
- #Mitochondrial Health
- Methylene Blue supports mitochondrial energy, reduces oxidative stress, and enhances mood and cognition by optimizing cellular energy production pathways.
- Alzheimer’s disease (AD) is increasingly viewed through the vascular-hypometabolism hypothesis, emphasizing cerebral hypoperfusion and mitochondrial dysfunction over amyloid plaques.
- Early-onset AD (EOAD) and late-onset AD (LOAD) differ significantly in etiology, with EOAD linked to genetic mutations and LOAD associated with vascular and metabolic factors.
- Cytochrome c oxidase (CO) deficits in the posterior cingulate cortex (PCC) correlate with AD progression, highlighting mitochondrial dysfunction as a key factor.
- Methylene Blue (MB) enhances mitochondrial function by acting as an alternative electron carrier, improving oxygen consumption and ATP production.
- Ketones serve as an alternative energy source for the brain, bypassing impaired glucose metabolism in AD.
- Near-infrared (NIR) light therapy stimulates CO activity, boosting mitochondrial function and cerebral blood flow.
- Combining MB, ketones, and NIR therapy offers a multimodal approach to addressing AD's metabolic and vascular deficits.
- AD is sometimes referred to as 'type 3 diabetes' due to its metabolic dysfunction links, with many AD patients also having type 2 diabetes or glucose abnormalities.
- Emerging interventions targeting mitochondrial and vascular health may outperform traditional amyloid-focused treatments for AD.